Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 120 entries
Sorted by: Best Match Show Resources per page
The future of high-grade glioma: Where we are and where are we going.

Surgical neurology international

Le Rhun E, Rhun EL, Taillibert S, Chamberlain MC.
PMID: 25722939
Surg Neurol Int. 2015 Feb 13;6:S9-S44. doi: 10.4103/2152-7806.151331. eCollection 2015.

High-grade glioma (HGG) are optimally treated with maximum safe surgery, followed by radiotherapy (RT) and/or systemic chemotherapy (CT). Recently, the treatment of newly diagnosed anaplastic glioma (AG) has changed, particularly in patients with 1p19q codeleted tumors. Results of trials...

Cite
Le Rhun E, Rhun EL, Taillibert S, et al. The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int. 2015;6:S9-S44doi: 10.4103/2152-7806.151331.
Le Rhun, E., Rhun, E. L., Taillibert, S., & Chamberlain, M. C. (2015). The future of high-grade glioma: Where we are and where are we going. Surgical neurology international, 6S9-S44. https://doi.org/10.4103/2152-7806.151331
Le Rhun, Emilie, et al. "The future of high-grade glioma: Where we are and where are we going." Surgical neurology international vol. 6 (2015): S9-S44. doi: https://doi.org/10.4103/2152-7806.151331
Le Rhun E, Rhun EL, Taillibert S, Chamberlain MC. The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int. 2015 Feb 13;6:S9-S44. doi: 10.4103/2152-7806.151331. eCollection 2015. PMID: 25722939; PMCID: PMC4338495.
Copy Download .nbib Format: NLM
A case of Takotsubo cardiomyopathy after chemotherapy.

Oxford medical case reports

Malley T, Watson E.
PMID: 27066260
Oxf Med Case Reports. 2016 Apr 07;2016(4):55-8. doi: 10.1093/omcr/omw014. eCollection 2016 Apr.

Here we present the case of a patient with diffuse large B-cell lymphoma who was admitted to hospital for an elective autologous peripheral blood stem cell transplant after cytotoxic treatment with lomustine, cytarabine, cyclophosphomide and etoposide (LACE). On the...

Cite
Malley T, Watson E. A case of Takotsubo cardiomyopathy after chemotherapy. Oxf Med Case Reports. 2016;2016(4):55-8doi: 10.1093/omcr/omw014.
Malley, T., & Watson, E. (2016). A case of Takotsubo cardiomyopathy after chemotherapy. Oxford medical case reports, 2016(4), 55-8. https://doi.org/10.1093/omcr/omw014
Malley, Tamir, and Watson, Edmund. "A case of Takotsubo cardiomyopathy after chemotherapy." Oxford medical case reports vol. 2016,4 (2016): 55-8. doi: https://doi.org/10.1093/omcr/omw014
Malley T, Watson E. A case of Takotsubo cardiomyopathy after chemotherapy. Oxf Med Case Reports. 2016 Apr 07;2016(4):55-8. doi: 10.1093/omcr/omw014. eCollection 2016 Apr. PMID: 27066260; PMCID: PMC4823761.
Copy Download .nbib Format: NLM
Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine.

Cureus

Drazin D, Al-Khouja L, Patel A, Hu J, Phuphanich S.
PMID: 26929887
Cureus. 2016 Jan 16;8(1):e460. doi: 10.7759/cureus.460.

Cediranib is an orally available, pan-VEGFR tyrosine kinase inhibitor. A previous Phase III study of patients with recurrent glioblastoma treated with this drug did not meet the primary end of progressive-free survival (PFS). We identified one patient, a 57-year-old...

Cite
Drazin D, Al-Khouja L, Patel A, et al. Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine. Cureus. 2016;8(1):e460doi: 10.7759/cureus.460.
Drazin, D., Al-Khouja, L., Patel, A., Hu, J., & Phuphanich, S. (2016). Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine. Cureus, 8(1), e460. https://doi.org/10.7759/cureus.460
Drazin, Doniel, et al. "Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine." Cureus vol. 8,1 (2016): e460. doi: https://doi.org/10.7759/cureus.460
Drazin D, Al-Khouja L, Patel A, Hu J, Phuphanich S. Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine. Cureus. 2016 Jan 16;8(1):e460. doi: 10.7759/cureus.460. PMID: 26929887; PMCID: PMC4757029.
Copy Download .nbib Format: NLM
Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study.

International journal of clinical and experimental medicine

Lv J, Zhu B, Zhang L, Xie Q, Zhuo W.
PMID: 25932168
Int J Clin Exp Med. 2015 Feb 15;8(2):2317-25. eCollection 2015.

Sorafenib, a novel orally-available multikinase inhibitor blocking several crucial oncogenic signaling pathways, presented survival benefits and became the first-line drug for treatment of patients with Hepatocellular carcinoma (HCC). However, the acquired resistance to Sorafenib resulted in limited benefits. In...

Cite
Lv J, Zhu B, Zhang L, et al. Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study. Int J Clin Exp Med. 2015;8(2):2317-25
Lv, J., Zhu, B., Zhang, L., Xie, Q., & Zhuo, W. (2015). Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study. International journal of clinical and experimental medicine, 8(2), 2317-25.
Lv, Jinli, et al. "Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study." International journal of clinical and experimental medicine vol. 8,2 (2015): 2317-25.
Lv J, Zhu B, Zhang L, Xie Q, Zhuo W. Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study. Int J Clin Exp Med. 2015 Feb 15;8(2):2317-25. eCollection 2015. PMID: 25932168; PMCID: PMC4402815.
Copy Download .nbib Format: NLM
Anaplastic oligodendroglioma: advances and treatment options.

Current treatment options in neurology

McNamara MG, Sahebjam S, Mason WP.
PMID: 23344797
Curr Treat Options Neurol. 2013 Jun;15(3):289-301. doi: 10.1007/s11940-013-0218-9.

OPINION STATEMENT: The optimal treatment strategy for anaplastic oligodendroglial (AO) tumors is evolving. Molecular profiling of oligodendrogliomas have shown distinctive genetic patterns characterized by combined deletions of chromosome arms 1p and 19q, O(6)-methylguanine methyltransferase (MGMT) methylation, and isocitrate dehydrogenase...

Cite
McNamara MG, Sahebjam S, Mason WP. Anaplastic oligodendroglioma: advances and treatment options. Curr Treat Options Neurol. 2013;15(3):289-301doi: 10.1007/s11940-013-0218-9.
McNamara, M. G., Sahebjam, S., & Mason, W. P. (2013). Anaplastic oligodendroglioma: advances and treatment options. Current treatment options in neurology, 15(3), 289-301. https://doi.org/10.1007/s11940-013-0218-9
McNamara, Mairéad G, et al. "Anaplastic oligodendroglioma: advances and treatment options." Current treatment options in neurology vol. 15,3 (2013): 289-301. doi: https://doi.org/10.1007/s11940-013-0218-9
McNamara MG, Sahebjam S, Mason WP. Anaplastic oligodendroglioma: advances and treatment options. Curr Treat Options Neurol. 2013 Jun;15(3):289-301. doi: 10.1007/s11940-013-0218-9. PMID: 23344797.
Copy Download .nbib Format: NLM
Successful treatment by chemotherapy of pineal parenchymal tumor with intermediate differentiation: a case report.

Cancer research and treatment

Yi JW, Kim HJ, Choi YJ, Seol YM, Kahng DH, Choi YY, Park EK.
PMID: 24155685
Cancer Res Treat. 2013 Sep;45(3):244-9. doi: 10.4143/crt.2013.45.3.244. Epub 2013 Sep 30.

A 37-year-old male presented with a mass measuring 2.5 cm in size in the midbrain and obstructive hydrocephalus, which had manifested as a headache and dizziness. Magnetic resonance (MR) imaging of the brain showed intermediate enhancement on T1-weighted MR...

Cite
Yi JW, Kim HJ, Choi YJ, et al. Successful treatment by chemotherapy of pineal parenchymal tumor with intermediate differentiation: a case report. Cancer Res Treat. 2013;45(3):244-9doi: 10.4143/crt.2013.45.3.244.
Yi, J. W., Kim, H. J., Choi, Y. J., Seol, Y. M., Kahng, D. H., Choi, Y. Y., & Park, E. K. (2013). Successful treatment by chemotherapy of pineal parenchymal tumor with intermediate differentiation: a case report. Cancer research and treatment, 45(3), 244-9. https://doi.org/10.4143/crt.2013.45.3.244
Yi, Ji-Won, et al. "Successful treatment by chemotherapy of pineal parenchymal tumor with intermediate differentiation: a case report." Cancer research and treatment vol. 45,3 (2013): 244-9. doi: https://doi.org/10.4143/crt.2013.45.3.244
Yi JW, Kim HJ, Choi YJ, Seol YM, Kahng DH, Choi YY, Park EK. Successful treatment by chemotherapy of pineal parenchymal tumor with intermediate differentiation: a case report. Cancer Res Treat. 2013 Sep;45(3):244-9. doi: 10.4143/crt.2013.45.3.244. Epub 2013 Sep 30. PMID: 24155685; PMCID: PMC3804738.
Copy Download .nbib Format: NLM
Hemophagocytic syndrome in a cat.

JFMS open reports

Wilkinson AR, Carr SV, Klahn SL, Dervisis NG, Hanks CR.
PMID: 30181894
JFMS Open Rep. 2018 Aug 27;4(2):2055116918795023. doi: 10.1177/2055116918795023. eCollection 2018.

CASE SUMMARY: A 12-year-old male castrated domestic shorthair cat was evaluated for a 10 month history of weight loss. Thin body condition and a grade II/VI systolic parasternal heart murmur was noted during examination. Moderate-to-severe anemia and intermittent thrombocytopenia...

Cite
Wilkinson AR, Carr SV, Klahn SL, et al. Hemophagocytic syndrome in a cat. JFMS Open Rep. 2018;4(2):2055116918795023doi: 10.1177/2055116918795023.
Wilkinson, A. R., Carr, S. V., Klahn, S. L., Dervisis, N. G., & Hanks, C. R. (2018). Hemophagocytic syndrome in a cat. JFMS open reports, 4(2), 2055116918795023. https://doi.org/10.1177/2055116918795023
Wilkinson, Ashley R, et al. "Hemophagocytic syndrome in a cat." JFMS open reports vol. 4,2 (2018): 2055116918795023. doi: https://doi.org/10.1177/2055116918795023
Wilkinson AR, Carr SV, Klahn SL, Dervisis NG, Hanks CR. Hemophagocytic syndrome in a cat. JFMS Open Rep. 2018 Aug 27;4(2):2055116918795023. doi: 10.1177/2055116918795023. eCollection 2018. PMID: 30181894; PMCID: PMC6113740.
Copy Download .nbib Format: NLM
Procarbazine, lomustine and vincristine toxicity in low-grade gliomas.

Current oncology (Toronto, Ont.)

Jutras G, Bélanger K, Letarte N, Adam JP, Roberge D, Lemieux B, Lemieux-Blanchard É, Masucci L, Ménard C, Bahary JP, Moumdjian R, Berthelet F, Florescu M.
PMID: 29507493
Curr Oncol. 2018 Feb;25(1):e33-e39. doi: 10.3747/co.25.3680. Epub 2018 Feb 28.

BACKGROUND: Procarbazine, lomustine, and vincristine (pcv) significantly improve survival outcomes in lgg (low-grade gliomas). Administration of pcv to lgg patients increased tremendously over the past years as it went from 2 patients per year between 2005 and 2012 to...

Cite
Jutras G, Bélanger K, Letarte N, et al. Procarbazine, lomustine and vincristine toxicity in low-grade gliomas. Curr Oncol. 2018;25(1):e33-e39doi: 10.3747/co.25.3680.
Jutras, G., Bélanger, K., Letarte, N., Adam, J. P., Roberge, D., Lemieux, B., Lemieux-Blanchard, �. �., Masucci, L., Ménard, C., Bahary, J. P., Moumdjian, R., Berthelet, F., & Florescu, M. (2018). Procarbazine, lomustine and vincristine toxicity in low-grade gliomas. Current oncology (Toronto, Ont.), 25(1), e33-e39. https://doi.org/10.3747/co.25.3680
Jutras, G, et al. "Procarbazine, lomustine and vincristine toxicity in low-grade gliomas." Current oncology (Toronto, Ont.) vol. 25,1 (2018): e33-e39. doi: https://doi.org/10.3747/co.25.3680
Jutras G, Bélanger K, Letarte N, Adam JP, Roberge D, Lemieux B, Lemieux-Blanchard É, Masucci L, Ménard C, Bahary JP, Moumdjian R, Berthelet F, Florescu M. Procarbazine, lomustine and vincristine toxicity in low-grade gliomas. Curr Oncol. 2018 Feb;25(1):e33-e39. doi: 10.3747/co.25.3680. Epub 2018 Feb 28. PMID: 29507493; PMCID: PMC5832288.
Copy Download .nbib Format: NLM
LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation.

Frontiers in oncology

Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, Dima D, Lupu A, Coriu D, Tomuleasa C, Tanase A.
PMID: 31552193
Front Oncol. 2019 Sep 10;9:892. doi: 10.3389/fonc.2019.00892. eCollection 2019.

High-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplantation (ASCT) is widely used in patients with malignant lymphomas. In Europe over 8,000 ASCTs for lymphoma were performed out of a total of 40,000 transplants according to the European...

Cite
Colita A, Colita A, Bumbea H, et al. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol. 2019;9:892doi: 10.3389/fonc.2019.00892.
Colita, A., Colita, A., Bumbea, H., Croitoru, A., Orban, C., Lipan, L. E., Craciun, O. G., Soare, D., Ghimici, C., Manolache, R., Gelatu, I., Vladareanu, A. M., Pasca, S., Teodorescu, P., Dima, D., Lupu, A., Coriu, D., Tomuleasa, C., & Tanase, A. (2019). LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Frontiers in oncology, 9892. https://doi.org/10.3389/fonc.2019.00892
Colita, Andrei, et al. "LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation." Frontiers in oncology vol. 9 (2019): 892. doi: https://doi.org/10.3389/fonc.2019.00892
Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, Dima D, Lupu A, Coriu D, Tomuleasa C, Tanase A. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol. 2019 Sep 10;9:892. doi: 10.3389/fonc.2019.00892. eCollection 2019. PMID: 31552193; PMCID: PMC6746965.
Copy Download .nbib Format: NLM
Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.

Journal of clinical medicine

Zeiner PS, Kinzig M, Divé I, Maurer GD, Filipski K, Harter PN, Senft C, Bähr O, Hattingen E, Steinbach JP, Sörgel F, Voss M, Steidl E, Ronellenfitsch MW.
PMID: 31766326
J Clin Med. 2019 Nov 21;8(12). doi: 10.3390/jcm8122031.

(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated a survival benefit for patients with first recurrence of a glioblastoma when treated with the multikinase inhibitor regorafenib (REG) instead of lomustine. The aim of this retrospective...

Cite
Zeiner PS, Kinzig M, Divé I, et al. Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. J Clin Med. 2019;8(12)doi: 10.3390/jcm8122031.
Zeiner, P. S., Kinzig, M., Divé, I., Maurer, G. D., Filipski, K., Harter, P. N., Senft, C., Bähr, O., Hattingen, E., Steinbach, J. P., Sörgel, F., Voss, M., Steidl, E., & Ronellenfitsch, M. W. (2019). Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. Journal of clinical medicine, 8(12), . https://doi.org/10.3390/jcm8122031
Zeiner, Pia S, et al. "Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients." Journal of clinical medicine vol. 8,12 (2019). doi: https://doi.org/10.3390/jcm8122031
Zeiner PS, Kinzig M, Divé I, Maurer GD, Filipski K, Harter PN, Senft C, Bähr O, Hattingen E, Steinbach JP, Sörgel F, Voss M, Steidl E, Ronellenfitsch MW. Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. J Clin Med. 2019 Nov 21;8(12). doi: 10.3390/jcm8122031. PMID: 31766326; PMCID: PMC6947028.
Copy Download .nbib Format: NLM
Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis.

OncoTargets and therapy

Song J, Xue YQ, Zhao MM, Xu P.
PMID: 29942135
Onco Targets Ther. 2018 Jun 13;11:3435-3439. doi: 10.2147/OTT.S160685. eCollection 2018.

BACKGROUND: Glioblastomas (GBMs) are the most aggressive type of glial brain tumors. Despite aggressive treatment with surgery and chemoradiation, GBMs invariably relapse and tumors are progressive. Controversy remains on optimal treatment of patients with recurrent GBMs. Data from previous...

Cite
Song J, Xue YQ, Zhao MM, et al. Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis. Onco Targets Ther. 2018;11:3435-3439doi: 10.2147/OTT.S160685.
Song, J., Xue, Y. Q., Zhao, M. M., & Xu, P. (2018). Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis. OncoTargets and therapy, 113435-3439. https://doi.org/10.2147/OTT.S160685
Song, Jie, et al. "Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis." OncoTargets and therapy vol. 11 (2018): 3435-3439. doi: https://doi.org/10.2147/OTT.S160685
Song J, Xue YQ, Zhao MM, Xu P. Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis. Onco Targets Ther. 2018 Jun 13;11:3435-3439. doi: 10.2147/OTT.S160685. eCollection 2018. PMID: 29942135; PMCID: PMC6005326.
Copy Download .nbib Format: NLM
High-grade gliomas.

Current treatment options in neurology

Theeler BJ, Groves MD.
PMID: 21499746
Curr Treat Options Neurol. 2011 Aug;13(4):386-99. doi: 10.1007/s11940-011-0130-0.

OPINION STATEMENT: High-grade gliomas (HGGs) should be treated with maximal, safe surgical resection followed by 57-60 Gy of partial-field external beam or intensity-modulated radiotherapy to a 2 cm margin surrounding the resection cavity. The standard of care for newly...

Cite
Theeler BJ, Groves MD. High-grade gliomas. Curr Treat Options Neurol. 2011;13(4):386-99doi: 10.1007/s11940-011-0130-0.
Theeler, B. J., & Groves, M. D. (2011). High-grade gliomas. Current treatment options in neurology, 13(4), 386-99. https://doi.org/10.1007/s11940-011-0130-0
Theeler, Brett J, and Groves, Morris D. "High-grade gliomas." Current treatment options in neurology vol. 13,4 (2011): 386-99. doi: https://doi.org/10.1007/s11940-011-0130-0
Theeler BJ, Groves MD. High-grade gliomas. Curr Treat Options Neurol. 2011 Aug;13(4):386-99. doi: 10.1007/s11940-011-0130-0. PMID: 21499746.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 120 entries